<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39273462</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>17</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>The Current Landscape of Secondary Malignancies after CAR T-Cell Therapies: How Could Malignancies Be Prevented?</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">9518</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms25179518</ELocationID><Abstract><AbstractText>Chimeric antigen receptor (CAR) T-cell therapies have revolutionised the field of haematological malignancies by achieving impressive remission rates in patients with highly refractory haematological malignancies, improving overall survival. To date, six commercial anti-CD19 and anti-BCMA CAR T-cell products have been approved by the Food and Drug Administration (FDA) for the treatment of relapsed/refractory B-cell haematological malignancies and multiple myeloma. The indications for CAR T-cell therapies are gradually expanding, with these therapies being investigated in a variety of diseases, including non-malignant ones. Despite the great success, there are several challenges surrounding CAR T-cell therapies, such as non-durable responses and high-grade toxicities. In addition, a new safety concern was added by the FDA on 28 November 2023 following reports of T-cell malignancies in patients previously treated with either anti-CD19 or anti-BCMA autologous CAR T-cell therapies both in clinical trials and in the real-world setting. Since then, several reports have been published presenting the incidence and analysing the risks of other secondary malignancies after CAR T-cell therapies. In this opinion article, the current landscape of secondary malignancies after CAR T-cell therapies is presented, along with a proposed strategy for future research aiming at potentially diminishing or abrogating the risk of developing secondary malignancies after CAR T-cell therapies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bouziana</LastName><ForeName>Stella</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7732-3885</Identifier><AffiliationInfo><Affiliation>Department of Hematology, King's College Hospital, London SE59RS, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouzianas</LastName><ForeName>Dimitrios</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-1750-657X</Identifier><AffiliationInfo><Affiliation>BReMeL, Biopharmaceutical and Regenerative Medicine Laboratories, 55534 Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018941">Antigens, CD19</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000076962">Receptors, Chimeric Antigen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016219" MajorTopicYN="Y">Immunotherapy, Adoptive</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018941" MajorTopicYN="N">Antigens, CD19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016609" MajorTopicYN="N">Neoplasms, Second Primary</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019337" MajorTopicYN="N">Hematologic Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000076962" MajorTopicYN="N">Receptors, Chimeric Antigen</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009101" MajorTopicYN="N">Multiple Myeloma</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CAR T-cell therapies</Keyword><Keyword MajorTopicYN="N">genome editing</Keyword><Keyword MajorTopicYN="N">genotoxicity</Keyword><Keyword MajorTopicYN="N">relapsed/refractory haematological malignancies</Keyword><Keyword MajorTopicYN="N">secondary T-cell lymphomas/leukaemias</Keyword><Keyword MajorTopicYN="N">secondary malignancies</Keyword><Keyword MajorTopicYN="N">viral vectors</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>14</Day><Hour>10</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>14</Day><Hour>10</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>14</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39273462</ArticleId><ArticleId IdType="pmc">PMC11395546</ArticleId><ArticleId IdType="doi">10.3390/ijms25179518</ArticleId><ArticleId IdType="pii">ijms25179518</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Guerra E., Di Pietro R., Basile M., Trerotola M., Alberti S. Cancer-Homing CAR-T Cells and Endogenous Immune Population Dynamics. Int. J. Mol. Sci. 2022;23:405. doi: 10.3390/ijms23010405.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23010405</ArticleId><ArticleId IdType="pmc">PMC8745734</ArticleId><ArticleId IdType="pubmed">35008832</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala Ceja M., Khericha M., Harris C.M., Puig-Saus C., Chen Y.Y. CAR-T cell manufacturing: Major process parameters and next-generation strategies. J. Exp. Med. 2024;221:e20230903. doi: 10.1084/jem.20230903.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20230903</ArticleId><ArticleId IdType="pmc">PMC10791545</ArticleId><ArticleId IdType="pubmed">38226974</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra A., Barua A., Huang L., Ganguly S., Feng Q., He B. From bench to bedside: The history and progress of CAR T cell therapy. Front. Immunol. 2023;14:1188049. doi: 10.3389/fimmu.2023.1188049.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1188049</ArticleId><ArticleId IdType="pmc">PMC10225594</ArticleId><ArticleId IdType="pubmed">37256141</ArticleId></ArticleIdList></Reference><Reference><Citation>Asmamaw Dejenie T., Tiruneh G/Medhin M., Dessie Terefe G., Tadele Admasu F., Wale Tesega W., Chekol Abebe E. Current updates on generations, approvals, and clinical trials of CAR T-cell therapy. Hum. Vaccin. Immunother. 2022;18:2114254. doi: 10.1080/21645515.2022.2114254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2022.2114254</ArticleId><ArticleId IdType="pmc">PMC9746433</ArticleId><ArticleId IdType="pubmed">36094837</ArticleId></ArticleIdList></Reference><Reference><Citation>Korell F., Berger T.R., Maus M.V. Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes. Med. 2022;3:538–564. doi: 10.1016/j.medj.2022.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2022.05.001</ArticleId><ArticleId IdType="pubmed">35963235</ArticleId></ArticleIdList></Reference><Reference><Citation>Neelapu S.S., Jacobson C.A., Ghobadi A., Miklos D.B., Lekakis L.J., Oluwole O.O., Lin Y., Braunschweig I., Hill B.T., Timmerman J.M., et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023;141:2307–2315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10646788</ArticleId><ArticleId IdType="pubmed">36821768</ArticleId></ArticleIdList></Reference><Reference><Citation>Laetsch T.W., Maude S.L., Rives S., Hiramatsu H., Bittencourt H., Bader P., Baruchel A., Boyer M., De Moerloose B., Qayed M., et al. Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial. J. Clin. Oncol. 2023;41:1664–1669. doi: 10.1200/JCO.22.00642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.22.00642</ArticleId><ArticleId IdType="pmc">PMC10022844</ArticleId><ArticleId IdType="pubmed">36399695</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin T., Usmani S.Z., Berdeja J.G., Agha M., Cohen A.D., Hari P., Avigan D., Deol A., Htut M., Lesokhin A., et al. Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J. Clin. Oncol. 2023;41:1265–1274. doi: 10.1200/JCO.22.00842.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.22.00842</ArticleId><ArticleId IdType="pmc">PMC9937098</ArticleId><ArticleId IdType="pubmed">35658469</ArticleId></ArticleIdList></Reference><Reference><Citation>Approved Cellular and Gene Therapy Products. US Food &amp; Drug Administration.  [(accessed on 26 April 2024)]; Available online:  https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products.</Citation></Reference><Reference><Citation>U.S. FDA Approves Bristol Myers Squibb’s Breyanzi as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)  [(accessed on 3 March 2024)].  Available online:  https://news.bms.com/news/details/2024/U.S.-FDA-Approves-Bristol-Myers-Squibbs-Breyanzi--as-the-First-and-Only-CAR-T-Cell-Therapy-for-Adults-with-Relapsed-or-Refractory-Chronic-Lymphocytic-Leukemia-CLL-or-Small-Lymphocytic-Lymphoma-SLL/default.aspx.</Citation></Reference><Reference><Citation>Melenhorst J.J., Chen G.M., Wang M., Porter D.L., Chen C., Collins M.A., Gao P., Bandyopadhyay S., Sun H., Zhao Z., et al. Decade-long leukemia remissions with the persistence of CD4+ CAR T cells. Nature. 2022;602:503–509. doi: 10.1038/s41586-021-04390-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04390-6</ArticleId><ArticleId IdType="pmc">PMC9166916</ArticleId><ArticleId IdType="pubmed">35110735</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouziana S., Bouzianas D. Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy. Crit. Rev. Oncol. Hematol. 2021;157:103096. doi: 10.1016/j.critrevonc.2020.103096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.critrevonc.2020.103096</ArticleId><ArticleId IdType="pubmed">33181441</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimitri A., Herbst F., Fraietta J.A. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Mol. Cancer. 2022;21:78. doi: 10.1186/s12943-022-01559-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-022-01559-z</ArticleId><ArticleId IdType="pmc">PMC8932053</ArticleId><ArticleId IdType="pubmed">35303871</ArticleId></ArticleIdList></Reference><Reference><Citation>Young R.M., Engel N.W., Uslu U., Wellhausen N., June C.H. Next-Generation CAR T-cell Therapies. Cancer Discov. 2022;12:1625–1633. doi: 10.1158/2159-8290.CD-21-1683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-21-1683</ArticleId><ArticleId IdType="pmc">PMC9262817</ArticleId><ArticleId IdType="pubmed">35417527</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamin R., Jain N., Maus M.V., Boissel N., Graham C., Jozwik A., Yallop D., Konopleva M., Frigault M.J., Teshima T., et al. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): A phase 1, dose-escalation trial. Lancet Haematol. 2022;9:e833–e843. doi: 10.1016/S2352-3026(22)00245-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(22)00245-9</ArticleId><ArticleId IdType="pubmed">36228643</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiegel J.Y., Jain M.D., Nastoupil L.J., Tamaresis J., Ghobadi A., Lin Y., Lekakis L.J., Reagan P.M., Oluwole O.O., McGuirk J.P., et al. Five year outcomes of patients with large B-Cell lymphoma treated with standard-of-care Axicabtagene Ciloleucel: Results from the US lymphoma CAR-T cell consortium. Blood. 2023;142((Suppl. S1)):1032. doi: 10.1182/blood-2023-179868.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2023-179868</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Brudno J.N., Kochenderfer J.N. Current understanding and management of CAR T cell-associated toxicities. Nat. Rev. Clin. Oncol. 2024;21:501–521. doi: 10.1038/s41571-024-00903-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41571-024-00903-0</ArticleId><ArticleId IdType="pubmed">38769449</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong W., Xiao Z., Qin Z., Yang J., Wen Y., Yu Z., Li Y., Sheppard N.C., Fuchs S.Y., Xu X., et al. Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors. Cancer Res. 2023;83:2790–2806. doi: 10.1158/0008-5472.CAN-22-2220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-22-2220</ArticleId><ArticleId IdType="pmc">PMC10524031</ArticleId><ArticleId IdType="pubmed">37115855</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackensen A., Müller F., Mougiakakos D., Böltz S., Weilhem A., Aigner M., Völkl S., Simon D., Kleyer A., Munoz L., et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 2022;28:2124–2132. doi: 10.1038/s41591-022-02017-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02017-5</ArticleId><ArticleId IdType="pubmed">36109639</ArticleId></ArticleIdList></Reference><Reference><Citation>Müller F., Taubmann J., Bucci L., Wilhelm A., Bergmann C., Völkl S., Aigner M., Rothe T., Minopoulou I., Tur C., et al. CD19 CAR T-Cell Therapy in Autoimmune Disease—A Case Series with Follow-up. N. Engl. J. Med. 2024;390:687–700. doi: 10.1056/NEJMoa2308917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2308917</ArticleId><ArticleId IdType="pubmed">38381673</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker D.J., Arany Z., Baur J.A., Epstein J.A., June C.H. CAR T therapy beyond cancer: The evolution of a living drug. Nature. 2023;619:707–715. doi: 10.1038/s41586-023-06243-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06243-w</ArticleId><ArticleId IdType="pubmed">37495877</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies. US Food &amp; Drug Administration.  [(accessed on 28 November 2023)]; Available online:  https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous.</Citation></Reference><Reference><Citation>Verdun N., Marks P. Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy. N. Engl. J. Med. 2024;390:584–586. doi: 10.1056/NEJMp2400209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp2400209</ArticleId><ArticleId IdType="pubmed">38265704</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine B.L., Pasquini M.C., Connolly J.E., Porter D.L., Gustafson M.P., Boelens J.J., Horwitz E.M., Grupp S.A., Maus M.V., Locke F.L., et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat. Med. 2024;30:338–341. doi: 10.1038/s41591-023-02767-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-023-02767-w</ArticleId><ArticleId IdType="pubmed">38195751</ArticleId></ArticleIdList></Reference><Reference><Citation>Elsallab M., Ellithi M., Lunning M.A., D’Angelo C., Ma J., Perales M.A., Frigault M., Maus M.V. Second Primary Malignancies After Commercial CAR T Cell Therapy: Analysis of FDA Adverse Events Reporting System (FAERS) Blood. 2024;143:2099–2105. doi: 10.1182/blood.2024024166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2024024166</ArticleId><ArticleId IdType="pubmed">38483155</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA Requires Boxed Warning for T cell Malignancies Following Treatment with BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies. US Food &amp; Drug Administration.  [(accessed on 18 April 2024)]; Available online:  https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-requires-boxed-warning-t-cell-malignancies-following-treatment-bcma-directed-or-cd19-directed.</Citation></Reference><Reference><Citation>Harrison S.J., Nguyen T., Rahman M., Er J., Li J., Li K., Lendvai N., Schecter J.M., Banerjee A., Roccia T., et al. CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma. Blood. 2023;142((Suppl. S1)):6939. doi: 10.1182/blood-2023-178806.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2023-178806</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinrich T., Rengstl B., Muik A., Petkova M., Schmid F., Wistinghausen R., Warner K., Crispatzu G., Hansmann M.L., Herling M., et al. Mature T-cell lymphomagenesis induced by retroviral insertional activation of Janus kinase 1. Mol. Ther. 2013;21:1160–1168. doi: 10.1038/mt.2013.67.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2013.67</ArticleId><ArticleId IdType="pmc">PMC3677306</ArticleId><ArticleId IdType="pubmed">23609016</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghilardi G., Fraietta J.A., Gerson J.N., Van Deerlin V.M., Morrissette J.J.D., Caponetti G.C., Paruzzo L., Harris J.C., Chong E.A., Susanibar Adaniya S.P., et al. T-cell Lymphoma and Secondary Primary Malignancy Risk After Commercial CAR T-cell Therapy. Nat. Med. 2024;30:984–989. doi: 10.1038/s41591-024-02826-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-024-02826-w</ArticleId><ArticleId IdType="pubmed">38266761</ArticleId></ArticleIdList></Reference><Reference><Citation>Bishop D.C., Clancy L.E., Simms R., Burgess J., Mathew G., Moezzi L., Street J.A., Sutrave G., Atkins E., McGuire H.M., et al. Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells. Blood. 2021;138:1504–1509. doi: 10.1182/blood.2021010813.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2021010813</ArticleId><ArticleId IdType="pubmed">34010392</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P., Yu W.J., Zhou L., Yang M., Ye S., Zhu J., Huang J., Zhang Y., Li L., Zhao J., et al. C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up. Blood. 2023;142((Suppl. S1)):1025. doi: 10.1182/blood-2023-182817.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2023-182817</ArticleId></ArticleIdList></Reference><Reference><Citation>Steffin D.H.M., Muhsen I.N., Hill L.C., Ramos C.A., Ahmed N., Hegde M., Wang T., Wu M., Gottschalk S., Whittle S.B., et al. Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022;140:16–24. doi: 10.1182/blood.2022015728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2022015728</ArticleId><ArticleId IdType="pmc">PMC9346960</ArticleId><ArticleId IdType="pubmed">35325065</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton M.P., Sugio T., Noordenbos T., Shi S., Bulterys P.L., Liu C.L., Kang X., Olsen M.N., Good Z., Dahiya S., et al. Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy. N. Engl. J. Med. 2024;390:2047–2060. doi: 10.1056/NEJMoa2401361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2401361</ArticleId><ArticleId IdType="pmc">PMC11338600</ArticleId><ArticleId IdType="pubmed">38865660</ArticleId></ArticleIdList></Reference><Reference><Citation>Chihara D., Dores G.M., Flowers C.R., Morton L.M. The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma. Blood. 2021;138:785–789. doi: 10.1182/blood.2020010497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020010497</ArticleId><ArticleId IdType="pmc">PMC8414260</ArticleId><ArticleId IdType="pubmed">33822002</ArticleId></ArticleIdList></Reference><Reference><Citation>Wartewig T., Kurgyis Z., Keppler S., Pechloff K., Hameister E., Öllinger R., Maresch R., Buch T., Steiger K., Winter C., et al. PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis. Nature. 2017;552:121–125. doi: 10.1038/nature24649.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature24649</ArticleId><ArticleId IdType="pmc">PMC5821214</ArticleId><ArticleId IdType="pubmed">29143824</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong E.A., Ruella M., Schuster S.J. Lymphoma Program Investigators at the University of Pennsylvania. Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy. N. Engl. J. Med. 2021;384:673–674. doi: 10.1056/NEJMc2030164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2030164</ArticleId><ArticleId IdType="pubmed">33596362</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordeiro A., Bezerra E.D., Hirayama A.V., Hill J.A., Wu Q.V., Voutsinas J., Sorror M.L., Turtle C.J., Maloney D.G., Bar M. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells. Biol. Blood Marrow Transpl. 2020;26:26–33. doi: 10.1016/j.bbmt.2019.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbmt.2019.08.003</ArticleId><ArticleId IdType="pmc">PMC6953906</ArticleId><ArticleId IdType="pubmed">31419568</ArticleId></ArticleIdList></Reference><Reference><Citation>Tward J.D., Wendland M.M., Shrieve D.C., Szabo A., Gaffney D.K. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer. 2006;107:108–115. doi: 10.1002/cncr.21971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.21971</ArticleId><ArticleId IdType="pubmed">16708354</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh E.M., Myers R.M., Yates B., Annesley C., John S., Taraseviciute A., Steinberg S.M., Sheppard J., Chung P., Chen L., et al. Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy. Blood Adv. 2022;6:5222–5226. doi: 10.1182/bloodadvances.2022008093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2022008093</ArticleId><ArticleId IdType="pmc">PMC9631644</ArticleId><ArticleId IdType="pubmed">35834728</ArticleId></ArticleIdList></Reference><Reference><Citation>Strati P., Varma A., Adkins S., Nastoupil L.J., Westin J., Hagemeister F.B., Fowler N.H., Lee H.J., Fayad L.E., Samaniego F., et al. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large b-cell lymphoma. Haematologica. 2021;106:2667–2672. doi: 10.3324/haematol.2020.254045.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2020.254045</ArticleId><ArticleId IdType="pmc">PMC8485681</ArticleId><ArticleId IdType="pubmed">32732355</ArticleId></ArticleIdList></Reference><Reference><Citation>Panagiota V., Kerschbaum J.F., Penack O., Stein C.M., Arends C.M., Koenecke C., Strzelecka P.M., Kloos A., Wiegand L., Lasch A., et al. Clinical implications and dynamics of clonal hematopoiesis in anti- CD19 CAR T-cell treated patients. Hemasphere. 2023;7:e957. doi: 10.1097/HS9.0000000000000957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HS9.0000000000000957</ArticleId><ArticleId IdType="pmc">PMC10550045</ArticleId><ArticleId IdType="pubmed">37799345</ArticleId></ArticleIdList></Reference><Reference><Citation>Teipel R., Kroschinsky F., Kramer M., Kretschmann T., Egger-Heidrich K., Krüger T., Ruhnke L., Herold S., Stasik S., Sockel K., et al. Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment. Blood Adv. 2022;6:1941–1946. doi: 10.1182/bloodadvances.2021005747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2021005747</ArticleId><ArticleId IdType="pmc">PMC8941459</ArticleId><ArticleId IdType="pubmed">35008107</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton M.P., Sworder B.J., Alig S.K., Good Z., Boegeholz J., Schroers-Martin J., Tamaresis J., Shahrokh Esfahani M., Lu Y., Olsen M., et al. CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias. Blood. 2023;142((Suppl. S1)):360. doi: 10.1182/blood-2023-182522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2023-182522</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkhateeb H.B., Mohty R., Greipp P., Bansal R., Hathcock M., Rosenthal A., Murth H., Kharfan-Dabaja M., Bisneto Villasboas J.C., Bennani N., et al. Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma. Blood Cancer J. 2022;12:113. doi: 10.1038/s41408-022-00707-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41408-022-00707-4</ArticleId><ArticleId IdType="pmc">PMC9325766</ArticleId><ArticleId IdType="pubmed">35882844</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller P.G., Sperling A.S., Brea E.J., Leick M.B., Fell G.G., Jan M., Gohil S.H., Tai Y.T., Munshi N.C., Wu C.J., et al. Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Adv. 2021;5:2982–2986. doi: 10.1182/bloodadvances.2021004554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2021004554</ArticleId><ArticleId IdType="pmc">PMC8361461</ArticleId><ArticleId IdType="pubmed">34342642</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmadreza A., Srikanthan J., Khelil M.B., Marcos-Kovandzik L., Amine-Hneineh R., Sabourin-Cousin M., Quivoron C., Christophe M., Baptiste Micol J., Zitvogel L., et al. CAR T cells reside in the bone marrow and inhibit hematopoiesis. HemaSphere. 2024;8((Suppl. S1)):2620.</Citation></Reference><Reference><Citation>Zhao A., Zhao M., Qian W., Liang A., Li P., Liu H. Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature. Front. Immunol. 2023;13:1063986. doi: 10.3389/fimmu.2022.1063986.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1063986</ArticleId><ArticleId IdType="pmc">PMC9880439</ArticleId><ArticleId IdType="pubmed">36713414</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacchi S., Marcheselli L., Bari A., Marcheselli R., Pozzi S., Luminari S., Lombardo M., Buda G., Lazzaro A., Gobbi P.G., et al. Secondary malignancies after treatment for indolent non-Hodgkin’s lymphoma: A 16-year follow-up study. Haematologica. 2008;93:398–404. doi: 10.3324/haematol.12120.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.12120</ArticleId><ArticleId IdType="pubmed">18268277</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee R., Poh C., Hirayama A.V., Gauthier J., Cassaday R.D., Shadman M., Cowan A.J., Till B.G., Green D.J., Kiem H.P., et al. Answering the “Doctor, can CAR-T therapy cause cancer?” question in clinic. Blood Adv. 2024;8:895–898. doi: 10.1182/bloodadvances.2023012336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2023012336</ArticleId><ArticleId IdType="pmc">PMC10875255</ArticleId><ArticleId IdType="pubmed">38197942</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M., Alkhateeb H., Shah S., Bansal R., Hathcock M., Rosenthal A., Kharfan-Dabaja M., Kourelis T., Patnaik M., Chen D., et al. Cytopenias, age and CAR-HEMATOTOX score predict the development of post CAR T-cell therapy-related myeloid neoplasms. Hemasphere. 2023;7((Suppl. S3)):e6718317. doi: 10.1097/01.HS9.0000967964.67183.17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.HS9.0000967964.67183.17</ArticleId></ArticleIdList></Reference><Reference><Citation>Galli E., Rossi M., Pansini I., Viscovo M., Malara T., Colangelo M., Alma E., Hohaus S., Sica S., Sorà F., et al. Predicting therapy-related myeloid neoplasms after CAR-T: Validation of the clonal hematopoiesis risk score (CHRS) HemaSphere. 2024;8((Suppl. S1)):398.</Citation></Reference><Reference><Citation>Levine B.L., Miskin J., Wonnacott K., Keir C. Global Manufacturing of CAR T Cell Therapy. Mol. Ther. Methods Clin. Dev. 2016;4:92–101. doi: 10.1016/j.omtm.2016.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtm.2016.12.006</ArticleId><ArticleId IdType="pmc">PMC5363291</ArticleId><ArticleId IdType="pubmed">28344995</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulcha J.T., Wang Y., Ma H., Tai P.W.L., Gao G. Viral vector platforms within the gene therapy landscape. Signal Transduct. Target. Ther. 2021;6:53. doi: 10.1038/s41392-021-00487-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00487-6</ArticleId><ArticleId IdType="pmc">PMC7868676</ArticleId><ArticleId IdType="pubmed">33558455</ArticleId></ArticleIdList></Reference><Reference><Citation>Howe S.J., Mansour M.R., Schwarzwaelder K., Bartholomae C., Hubank M., Kempski H., Brugman M.H., Pike-Overzet K., Chatters S.J., de Ridder D., et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Investig. 2008;118:3143–3150. doi: 10.1172/JCI35798.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI35798</ArticleId><ArticleId IdType="pmc">PMC2496964</ArticleId><ArticleId IdType="pubmed">18688286</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein S., Ott M.G., Schultze-Strasser S., Jauch A., Burwinkel B., Kinner A., Schmidt M., Krämer A., Schwäble J., Glimm H., et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med. 2010;16:198–204. doi: 10.1038/nm.2088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2088</ArticleId><ArticleId IdType="pubmed">20098431</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun C.J., Boztug K., Paruzynski A., Witzel M., Schwarzer A., Rothe M., Modlich U., Beier R., Göhring G., Steinemann D., et al. Gene therapy for Wiskott-Aldrich Syndrome—Long-term reconstitution and clinical benefits, but increased risk for leukemogenesis. Sci. Transl. Med. 2014;6:227ra33. doi: 10.1126/scitranslmed.3007280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3007280</ArticleId><ArticleId IdType="pubmed">24622513</ArticleId></ArticleIdList></Reference><Reference><Citation>Crystal R.G. Adenovirus: The first effective in vivo gene delivery vector. Hum. Gene Ther. 2014;25:3–11. doi: 10.1089/hum.2013.2527.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2013.2527</ArticleId><ArticleId IdType="pmc">PMC3900005</ArticleId><ArticleId IdType="pubmed">24444179</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooray S., Howe S.J., Thrasher A.J. Retrovirus and lentivirus vector design and methods of cell conditioning. Methods Enzymol. 2012;507:29–57.</Citation><ArticleIdList><ArticleId IdType="pubmed">22365768</ArticleId></ArticleIdList></Reference><Reference><Citation>David R.M., Doherty A.T. Viral Vectors: The Road to Reducing Genotoxicity. T Toxicol. Sci. 2017;155:315–325. doi: 10.1093/toxsci/kfw220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/toxsci/kfw220</ArticleId><ArticleId IdType="pubmed">27803388</ArticleId></ArticleIdList></Reference><Reference><Citation>Labbé R.P., Vessillier S., Rafiq Q.A. Lentiviral vectors for T cell engineering: Clinical applications, bioprocessing and future perspectives. Viruses. 2021;13:1528. doi: 10.3390/v13081528.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13081528</ArticleId><ArticleId IdType="pmc">PMC8402758</ArticleId><ArticleId IdType="pubmed">34452392</ArticleId></ArticleIdList></Reference><Reference><Citation>Moiani A., Paleari Y., Sartori D., Mezzadra R., Miccio A., Cattoglio C., Cocchiarella F., Lidonnici M.R., Ferrari G., Mavilio F. Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts. J. Clin. Investig. 2012;122:1653–1666. doi: 10.1172/JCI61852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI61852</ArticleId><ArticleId IdType="pmc">PMC3347495</ArticleId><ArticleId IdType="pubmed">22523069</ArticleId></ArticleIdList></Reference><Reference><Citation>Cesana D., Ranzani M., Volpin M., Bartholomae C., Duros C., Artus A., Merella S., Benedicenti F., Sergi Sergi L., Sanvito F., et al. Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo. Mol. Ther. 2014;22:774–785. doi: 10.1038/mt.2014.3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2014.3</ArticleId><ArticleId IdType="pmc">PMC3982501</ArticleId><ArticleId IdType="pubmed">24441399</ArticleId></ArticleIdList></Reference><Reference><Citation>Schubert M.L., Schmitt1 M., Wang L., Ramos C.A., Jordan K., Müller-Tidow C., Dreger P. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann. Oncol. 2021;32:34–48. doi: 10.1016/j.annonc.2020.10.478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2020.10.478</ArticleId><ArticleId IdType="pubmed">33098993</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraietta J.A., Nobles C.L., Sammons M.A., Lundh S., Carty S.A., Reich T.J., Cogdill A.P., Morrissette J.J.D., DeNizio J.E., Reddy S., et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature. 2018;558:307–312. doi: 10.1038/s41586-018-0178-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0178-z</ArticleId><ArticleId IdType="pmc">PMC6320248</ArticleId><ArticleId IdType="pubmed">29849141</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah N.N., Qin H., Yates B., Su L., Shalabi H., Raffeld M., Ahlman M.A., Stetler-Stevenson M., Yuan C., Guo S., et al. Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy. Blood Adv. 2019;3:2317–2322. doi: 10.1182/bloodadvances.2019000219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2019000219</ArticleId><ArticleId IdType="pmc">PMC6693002</ArticleId><ArticleId IdType="pubmed">31387880</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavazzana-Calvo M., Payen E., Negre O., Wang G., Hehir K., Fusil F., Down J., Denaro M., Brady T., Westerman K., et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature. 2010;467:318–322. doi: 10.1038/nature09328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09328</ArticleId><ArticleId IdType="pmc">PMC3355472</ArticleId><ArticleId IdType="pubmed">20844535</ArticleId></ArticleIdList></Reference><Reference><Citation>Eichler F., Duncan C., Musolino P.L., Orchard P.J., De Oliveira S., Thrasher A.J., Armant M., Dansereau C., Lund T.C., Miller W.P., et al. Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy. N. Engl. J. Med. 2017;377:1630–1638. doi: 10.1056/NEJMoa1700554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1700554</ArticleId><ArticleId IdType="pmc">PMC5708849</ArticleId><ArticleId IdType="pubmed">28976817</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A.O., Raymond G., Pierpont E.I., Kemp S., McIvor R.S., Rayannavar A., Miller B., Lund T.C., Orchard P.J. Treatment of cerebral adrenoleukodystrophy: Allogeneic transplantation and lentiviral gene therapy. Exp. Opin. Biol. Ther. 2022;22:1151–1162. doi: 10.1080/14712598.2022.2124857.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14712598.2022.2124857</ArticleId><ArticleId IdType="pubmed">36107226</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunson A., Keegan T.H.M., Bang H., Mahajan A., Paulukonis S., Wun T. Increased risk of leukemia among sickle cell disease patients in California. Blood. 2017;130:1597–1599. doi: 10.1182/blood-2017-05-783233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2017-05-783233</ArticleId><ArticleId IdType="pmc">PMC5620417</ArticleId><ArticleId IdType="pubmed">28830890</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal S., Tisdale J., Schmidt M., Kanter J., Jaroscak J., Whitney D., Bitter H., Gregory P.D., Parsons G., Foos M., et al. Acute myeloid leukemia case after gene therapy for sickle cell disease. N. Engl. J. Med. 2022;386:138–147. doi: 10.1056/NEJMoa2109167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2109167</ArticleId><ArticleId IdType="pubmed">34898140</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh M.M., Bonner M., Pierciey F.J., Uchida N., Rottman J., Demopoulos L., Schmidt M., Kanter J., Walters M.C., Thompson A.A., et al. Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease. Blood Adv. 2020;4:2058–2063. doi: 10.1182/bloodadvances.2019001330.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2019001330</ArticleId><ArticleId IdType="pmc">PMC7218414</ArticleId><ArticleId IdType="pubmed">32396618</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Newswire Uniqure Announces Findings from Reported Case of Hepatocellular Carcinoma (HCC) in Hemophilia B Gene Therapy Program.  [(accessed on 29 March 2021)].  Available online:  https://www.globenewswire.com/news-release/2021/03/29/2200653/0/en/uniQure-Announces-Findings-from-Reported-Case-of-Hepatocellular-Carcinoma-HCC-in-Hemophilia-B-Gene-Therapy-Program.html.</Citation></Reference><Reference><Citation>Chandler R.J., LaFave M.C., Varshney G.K., Trivedi N.S., Carrillo-Carrasco N., Senac J.S., Wu W., Hoffmann V., Elkahloun A.G., Burgess S.M., et al. Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J. Clin. Investig. 2015;125:870–880. doi: 10.1172/JCI79213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI79213</ArticleId><ArticleId IdType="pmc">PMC4319425</ArticleId><ArticleId IdType="pubmed">25607839</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen G.N., Everett J.K., Kafle S., Roche A.M., Raymond H.E., Leiby J., Wood C., Assenmacher C.A., Merricks E.P., Long C.T., et al. A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells. Nat. Biotechnol. 2021;39:47–55. doi: 10.1038/s41587-020-0741-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-020-0741-7</ArticleId><ArticleId IdType="pmc">PMC7855056</ArticleId><ArticleId IdType="pubmed">33199875</ArticleId></ArticleIdList></Reference><Reference><Citation>Nault J.C., Datta S., Imbeaud S., Franconi A., Mallet M., Couchy G., Letouzé E., Pilati C., Verret B., Blanc J.F., et al. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat. Genet. 2015;47:1187–1193. doi: 10.1038/ng.3389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3389</ArticleId><ArticleId IdType="pubmed">26301494</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Yang Y., Hong W., Huang M., Wu M., Zhao X. Applications of genome editing technology in the targeted therapy of human diseases: Mechanisms, advances and prospects. Signal Transduct. Target. Ther. 2020;5:1. doi: 10.1038/s41392-019-0089-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-019-0089-y</ArticleId><ArticleId IdType="pmc">PMC6946647</ArticleId><ArticleId IdType="pubmed">32296011</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease. US Food &amp; Drug Administration.  [(accessed on 8 December 2023)]; Available online:  www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease.</Citation></Reference><Reference><Citation>Liu X., Zhang Y., Cheng C., Cheng A.W., Zhang X., Li N., Xia C., Wei X., Liu X., Wang H. CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells. Cell Res. 2017;27:154–157. doi: 10.1038/cr.2016.142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cr.2016.142</ArticleId><ArticleId IdType="pmc">PMC5223227</ArticleId><ArticleId IdType="pubmed">27910851</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchida C.A., Brandes N., Bueno R., Trinidad M., Mazumder T., Yu B., Hwang B., Chang C., Liu J., Sun Y., et al. Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells. Cell. 2023;186:4567–4582. doi: 10.1016/j.cell.2023.08.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2023.08.041</ArticleId><ArticleId IdType="pmc">PMC10664023</ArticleId><ArticleId IdType="pubmed">37794590</ArticleId></ArticleIdList></Reference><Reference><Citation>Höijer I., Emmanouilidou A., Östlund R., van Schendel R., Bozorgpana S., Tijsterman M., Feuk L., Gyllensten U., den Hoed M., Ameur A. CRISPR-Cas9 induces large structural variants at on-target and off-target sites in vivo that segregate across generations. Nat. Commun. 2022;13:627. doi: 10.1038/s41467-022-28244-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-28244-5</ArticleId><ArticleId IdType="pmc">PMC8810904</ArticleId><ArticleId IdType="pubmed">35110541</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemmens M., Dorsheimer L., Zeller A., Dietz-Baum Y. Non-clinical safety assessment of novel drug modalities: Genome safety perspectives on viral-, nuclease- and nucleotide-based gene therapies. Mutat. Res. Genet. Toxicol. Environ. Mutagen. 2024;896:503767. doi: 10.1016/j.mrgentox.2024.503767.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mrgentox.2024.503767</ArticleId><ArticleId IdType="pubmed">38821669</ArticleId></ArticleIdList></Reference><Reference><Citation>Micklethwaite K.P., Gowrishankar K., Gloss B.S., Li Z., Street J.A., Moezzi L., Mach M.A., Sutrave G., Clancy L.E., Bishop D.C., et al. Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells. Blood. 2021;138:1401–1415. doi: 10.1182/blood.2021010858.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2021010858</ArticleId><ArticleId IdType="pmc">PMC8532197</ArticleId><ArticleId IdType="pubmed">33974080</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy L.A., Marians R.C., Miller K., Brenton M.D., Mallo R.L.V., Kohler M.E., Fry T.J., Winters A.C. Digital polymerase chain reaction strategies for accurate and precise detection of vector copy number in CAR T cell products. Cytotherapy. 2023;25:94–102. doi: 10.1016/j.jcyt.2022.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcyt.2022.09.004</ArticleId><ArticleId IdType="pmc">PMC10123956</ArticleId><ArticleId IdType="pubmed">36253252</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan N., Feng H., Sun Y., Xin Y., Zhang H., Lu H., Zheng J., He C., Zuo Z., Yuan T., et al. Cytosine base editors induce off-target mutations and adverse phenotypic effects in transgenic mice. Nat. Commun. 2023;14:1784. doi: 10.1038/s41467-023-37508-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-37508-7</ArticleId><ArticleId IdType="pmc">PMC10063651</ArticleId><ArticleId IdType="pubmed">36997536</ArticleId></ArticleIdList></Reference><Reference><Citation>Slesarenko Y.S., Lavrov A.V., Smirnikhina S.A. Off-target effects of base editors: What we know and how we can reduce it. Curr. Genet. 2022;68:39–48. doi: 10.1007/s00294-021-01211-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00294-021-01211-1</ArticleId><ArticleId IdType="pubmed">34515826</ArticleId></ArticleIdList></Reference><Reference><Citation>Odak A., Yuan H., Feucht J., Cantu V.A., Mansilla-Soto J., Kogel F., Eyquem J., Everett J., Bushman F.D., Leslie C.S., et al. Novel extragenic genomic safe harbors for precise therapeutic T-cell engineering. Blood. 2023;141:2698–2712. doi: 10.1182/blood.2022018924.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2022018924</ArticleId><ArticleId IdType="pmc">PMC10273162</ArticleId><ArticleId IdType="pubmed">36745870</ArticleId></ArticleIdList></Reference><Reference><Citation>Metzloff A.E., Padilla M.S., Gong N., Billingsley M.M., Han X., Merolle M., Mai D., Figueroa-Espada C.G., Thatte A.S., Haley R.M., et al. Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR T Cell Cancer Immunotherapy. Adv. Mater. 2024;36:e2313226. doi: 10.1002/adma.202313226.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adma.202313226</ArticleId><ArticleId IdType="pmc">PMC11209815</ArticleId><ArticleId IdType="pubmed">38419362</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J., Wu W., Zhou B., Li B. Chimeric antigen receptor therapy meets mRNA technology. Trends Biotech. 2024;42:228–240. doi: 10.1016/j.tibtech.2023.08.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibtech.2023.08.005</ArticleId><ArticleId IdType="pubmed">37741706</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouzianas D., Bouziana S. A decade of CD4+ chimeric antigen receptor T-cell evolution in two chronic lymphocytic leukemia patients: Were chronic lymphocytic leukemia cells present? Explor. Target. Antitumor Ther. 2023;4:1128–1135. doi: 10.37349/etat.2023.00186.</Citation><ArticleIdList><ArticleId IdType="doi">10.37349/etat.2023.00186</ArticleId><ArticleId IdType="pmc">PMC10645517</ArticleId><ArticleId IdType="pubmed">37970204</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouzianas D., Bouziana S. First pediatric B-acute lymphoblastic leukemia patient treated with anti-CD19 chimeric antigen receptor T-cell therapy: Long-term remission or early cure? Hum. Vaccines Immunother. 2024;20:2321678. doi: 10.1080/21645515.2024.2321678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2024.2321678</ArticleId><ArticleId IdType="pmc">PMC10898498</ArticleId><ArticleId IdType="pubmed">38402637</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>